Instrument Inactif

Communiqués Taisho Pharma

Actions

4535

JP3442800003

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Taisho Pharma : Notice Concerning the Termination of the Agreement Between Taisho Pharmaceutical Co., Ltd. and Takeda Pharmaceutical Co., Ltd. on the Distribution of the OTC Drugs and Quasi-Drugs of Biofermin Pharmaceutical Co., Ltd.(Taisho Pharmaceutical Holdings)	31/01/17	PU
Taisho Pharma : Completes Acquisition of 24.50% Shares in Duoc Hau Giang Pharmaceutical JSC( Pharmaceutical Holdings)	05/07/16	PU
Taisho Pharma : Agent for Osteoporosis Approved in Japan“Bonviva® Tablet”	22/01/16	PU
Taisho Pharma : Launch of the Transdermal Anti-inflammatory Analgesic Patch Formulation LOQOA® Tape(Taisho Pharmaceutical Holdings)	20/01/16	PU
Taisho Pharma : Ceremony Commemorating 20th Anniversary of Taurine Joint Venture	08/12/15	PU
Taisho Pharma : Notice of Changes in Board Members and Personnel of the Company and Its Consolidated Subsidiary(Taisho Pharmaceutical Holdings)	13/05/15	PU
Taisho Pharma : Signing of Domestic Sales Rights Licensing Agreement Regarding TT-063 Anti-inflammatory Analgesic Patch Formulation Containing S-Flurbiprofen(Taisho Pharmaceutical Holdings)	30/03/15	PU
Taisho Pharma : Results of Phase III Clinical Trial of Ibandronate Sodium Hydrate Oral Formulation, Bisphosphonate Antiresorptive Agent, in Japanese Patients with Osteoporosis Presented	30/03/15	PU
Taisho Pharma : New Drug Application Filed for Ibandronate Sodium Hydrate Oral Agent, Bisphosphonate Antiresorptive Agent	11/03/15	PU
Taisho Pharma : Filing for Manufacturing and Marketing Approval in Japan for TT-063 Anti-inflammatory Analgesic Patch Formulation Containing S-Flurbiprofen(Taisho Pharmaceutical Holdings)	20/10/14	PU
Taisho Pharma : Launch of Selective SGLT2 Inhibitor Lusefi® Tablets 2.5mg and Lusefi® Tablets 5mg(Taisho Pharmaceutical Holdings)	23/05/14	PU
Taisho Pharma : Notice of Change in Taisho Pharmaceutical Co., Ltd.'s Representative Director and Director(Taisho Pharmaceutical Holdings)	12/05/14	PU
Taisho Pharma : Acquisition of Manufacturing and Marketing Approval in Japan for SGLT2 Inhibitor Lusefi® Tablets 2.5mg and Lusefi® Tablets 5mg(Taisho Pharmaceutical Holdings)	24/03/14	PU
Taisho Pharma : Acquisition of Analgesic Brand in the Philippines Held by Roche Group (Taisho Pharmaceutical Holdings)	03/03/14	PU
Taisho Pharma : Notice Concerning Group Reorganization (Transfer of Group Company Subsidiary) (Taisho Pharmaceutical Holdings)	26/02/14	PU
Taisho Pharma : Results of Phase 3 Long-term Administration Clinical Trials of SGLT2 Inhibitor Luseogliflozin Hydrate (TS-071) in Japan Targeting Type 2 Diabetes Mellitus Patients Announced at World Diabetes Congress of IDF(Taisho Pharmaceutical Holdings)	03/12/13	PU
Taisho Pharma : SGLT2 Inhibitor Luseogliflozin Hydrate (TS-071): Results of Phase 3 Clinical Trials in Japan Targeting Type 2 Diabetes Mellitus Patients Announced at the 49th Annual Meeting of EASD(Taisho Pharmaceutical Holdings)	26/09/13	PU
Taisho Pharma : Notice of Acquisition of an Exclusive Distributorship for Products of Biofermin Pharmaceutical Co., Ltd. and Purchase of a Part of its Shares by Taisho Pharmaceutical Co., Ltd.(Taisho Pharmaceutical Holdings)	31/07/13	PU
Taisho Pharma : New Agent for Osteoporosis Approved in Japan “Bonviva® IV Injection”	29/06/13	PU
Taisho Pharma : Results of Phase II/III Clinical Trial of Ibandronate Sodium Hydrate Injection, Bisphosphonate Antiresorptive Agent, in Japanese Patients with Osteoporosis Presented	19/04/13	PU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Taisho Pharma

Actions

4535

JP3442800003

Communiqués

Filtres